Project Grant R44MH119989
- This Project Grant award of $348,373 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a novel family of biosensors that can be used to report on and dynamically regulate changes in neuroinflammation within the brains of live animals. The key products and services to be delivered through this grant include: 1) Developing and...
- The National Institutes of Health (NIH) Office of the Director awarded a $1,271,280 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the Allen Institute in Seattle, WA. The award, spanning September 2024 to September 2027, aims to develop two "exa-scale" (extremely high-throughput) tissue readout methods to transform the study of the brain. The first method will enable highly multiplexed molecular mapping of individual proteins across entire brains at the...
- Federal Grant Award Summary Translucence Biosystems, Inc. received a $375,000 Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) awarded September 20, 2025, with completion targeted for May 31, 2027. The company is developing and refining a Vasculature Subtraction Parenchymal Quantification (VSPQ) workflow—an advanced software tool integrated into its proprietary 3D brain imaging and analysis platform. This specialized tool...
- This National Science Foundation (NSF) Cooperative Agreement award under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $994,138 to Modendo Inc., a for-profit company located in Boulder, CO, to develop and validate a prototype ultrathin endomicroscope instrument for high-resolution, minimally invasive optical imaging of the brain in animal neuroscience research. The key innovation is achieving a cross-sectional area more than 10 times smaller than...
- The National Institutes of Health National Institute of Neurological Disorders and Stroke awarded $1,852,675 under the 21st Century Cures Act - Brain Research through Advancing Innovative Neurotechnologies program (CFDA 93.372) to the University of California, Los Angeles from August 1, 2022 to July 31, 2025. The award will support the development of light field tomographic microscopy for kilohertz volumetric imaging of neuronal action potentials in awake behaving mice. Specifically, the...
- Carolina Instruments, Inc. received a $789,416 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 8, 2025, with completion targeted for September 7, 2026. The company is developing a novel Biometric Ocular Photometry (BOP) system designed to simultaneously measure multiple physiological indicators—including pupil size, heart rate, and respiratory rate—in freely moving mice using photoplethysmography...
- This Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) provides $434,716 to the University of Oklahoma Health Sciences Center to develop a set of optical tools for capturing and interpreting high-speed recordings of neural activity across the entire zebrafish brain. The key objectives are to create fluorescent voltage sensors, optical microscopes, and signal processing algorithms that can simultaneously monitor millisecond-scale bursts of neural...
- Grant Award Summary The National Institute on Aging (NIA) awarded Tauvision, Inc. $986,768 under the Aging Research program (CFDA 93.866) to develop an innovative eyedrop-based diagnostic test for Alzheimer's disease (AD). The project, initiated September 20, 2025, with completion anticipated September 19, 2026, addresses the critical diagnostic gap in AD management by leveraging a proprietary fluorescent dye technology that labels pathological protein aggregates in the eye for imaging with...
- The National Institutes of Health (NIH) awarded a $1,385,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the Allen Institute, a non-profit research organization, to develop novel techniques for measuring the input-output operations of individual neurons in the mouse cortex. The project aims to overcome challenges in understanding how neurons in the mammalian brain transform their synaptic inputs into outputs, which is critical for designing effective brain-machine...
- Federal Project Grant Award Summary Objective Biotechnology, Inc. received a $416,925 Project Grant award from the National Institutes of Health Office of the Director under the Research Infrastructure Programs (CFDA 93.351) on September 15, 2025, with an ultimate completion date of August 31, 2027. The award supports the development and enhancement of the mini-mscope, a miniaturized imaging device designed for high-performance mesoscale neural activity measurement across the cerebral cortex...
RAPID EVALUATION OF NEURONAL ACTIVITY IN THE INTACT WHOLE BRAIN AT SINGLE CELL RESOLUTION - PROJECT SUMMARY HERE WE SEEK TO DEVELOP A "NEURONAL ACTIVITY QUANTITATIVE DIAGNOSTIC" PLATFORM AND REAGENT KITS TO DISSEMINATE ACCESSIBLE PRODUCTS FOR MEASURING RECENT NEURAL ACTIVITY ACROSS THE ENTIRE MOUSE BRAIN TO THE NEUROSCIENCE COMMUNITY. PREVIOUSLY WE HAVE SHOWN THAT THE ACTIVITY-DEPENDENT IMMEDIATE-EARLY GENE PROTEIN PRODUCTS NPAS4 AND CFOS CAN BE CLEARLY DETECTED, IMAGED, AND QUANTIFIED USING DEVELOPMENTAL VERSIONS OF OUR PLATFORM TOOLS. IMMEDIATE EARLY GENES ARE GENES THAT ARE ACTIVATED TRANSIENTLY AND RAPIDLY IN RESPONSE TO A WIDE VARIETY OF CELLULAR STIMULI. THE THREE OVERLAPPING AIMS TO BE INVESTIGATED IN THIS PHASE II PROJECT ARE: 1) DEMONSTRATION OF THE FIDELITY OF OUR ASSAY FOR OUR CUSTOMERS. TO DEMONSTRATE THE ROBUSTNESS AND ACCURACY OF OUR NEURONAL ACTIVITY ASSAY WITH ANOTHER WELL-KNOWN ASSAY FOR ACTIVITY, WE WILL PERFORM TWO PHOTON CALCIUM FLUORESCENCE IMAGING IN THE PRIMARY VISUAL CORTEX OF MICE PRESENTED WITH REPEATED VISUAL STIMULI. WE WILL CLEAR AND STAIN THE BRAINS FOR CFOS AND NPAS4 AND DEMONSTRATE THE FIDELITY OF THESE MARKERS FOR DETECTING RECENTLY ACTIVE NEURONS. 2) DEVELOP AND BETA TEST ROBUST VERSIONS OF OUR SOFTWARE TOOLS USEABLE BY RESEARCHERS WITH NO SPECIALIZED CODING OR STATISTICS KNOWLEDGE. WE WILL DEVELOP STITCHY AND BRAINSNAP INTO ROBUST, USER-FRIENDLY SOFTWARE PRODUCTS THAT REMOVE THE CURRENT ANALYSIS BOTTLENECK FOR NEUROSCIENTISTS INTERESTED IN WHOLE-BRAIN IMAGING. STITCHY WILL BE AN IMPROVED BROWSER-BASED VERSION OF OUR INTERNAL SOFTWARE THAT SIMPLIFIES AND SPEEDS THE PROCESS OF STITCHING TOGETHER LIGHT SHEET MICROSCOPE IMAGES. BRAINSNAP SOFTWARE WILL INTEGRATE OUR HIGH-PERFORMANCE 3TK- QUANT FRAMEWORK FOR MACHINE LEARNING-ENABLED QUANTIFICATION AND OUR STATISTICAL FRAMEWORK FOR WHOLE-BRAIN ANATOMICS, 3TK-STATS, IN A BROWSER-BASED INTERFACE. WE HAVE RECRUITED END USERS WHO WILL TEST THIS SOFTWARE IN A HEAD-TO-HEAD COMPARISON WITH OUR IN-HOUSE TESTING. 3) DEVELOP AND TEST A BRAIN CLEARING AND STAINING KIT FOR NEURONAL ACTIVITY. TO HELP RESEARCHERS PRODUCE HIGH QUALITY CLEARED BRAINS STAINED WITH NEURONAL ACTIVITY MARKERS, WE WILL GENERATE NEURONAL ACTIVITY CLEARING AND STAINING REAGENTS KITS FOR CFOS AND NPAS4. THESE WILL BE TESTED BY COLLABORATORS IN HEAD-TO-HEAD COMPARISONS WITH OUR IN-HOUSE PROCEDURES ON BRAINS PREPARED IN PARALLEL. AT THE END OF PHASE II, TRANSLUCENCE WILL HAVE A MARKET-READY NEURONAL ACTIVITY QUANTITATIVE DIAGNOSTIC PLATFORM INCLUDING REAGENT KITS, USER-FRIENDLY SOFTWARE, AND SERVICE OPTIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($6) | 4/24/25 | ||
| Not listed | $0 | 11/13/24 | ||
| Not listed | $0 | 11/13/24 | ||
| Not listed | $0 | 11/13/24 | ||
| Not listed | $0 | 11/13/24 |